跳至主要内容
临床试验/IRCT20210427051098N2
IRCT20210427051098N2招募中3 期

Investigating the effects of Nanocurcumin supplementation on fibrosis? steatosis? Inflammatory and metabolic status of liver fibrosis patients with non-alcoholic fatty liver origin

Yazd University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
30 years 至 70 years(—)
性别
All

入选标准

  • patients between 30 and 70 years of age with liver fibrosis F=2 referring to the liver and digestive consultation and treatment clinic

排除标准

  • History of alcohol intake or current intake of alcohol
  • evidence of other forms of chronic and acute liver diseases (such as viral hepatitis B, C etc), biliary disease, known autoimmune hepatitis and hereditary disorders affecting the liver (storage disease of iron, copper etc)
  • current pregnancy or breastfeeding
  • Use of hepatotoxic medication
  • current Lung and kidney disease
  • Drug abuse, history of cancer
  • Treatment with anti-inflammatory, corticosteroids and hormones medication
  • Use of weight loss medication or diets
  • Intolerance or allergy to the supplement
  • Unwillingness to participate in the study
  • Changes in the patient's medications
  • Patients with current warfarin medications

研究者

发起方
Yazd University of Medical Sciences

相似试验